InfraReDx’s LipiScan(TM) IVUS to be Featured in Live Case Demonstration at EuroPCR

BURLINGTON, Mass., May 27 /PRNewswire/ -- InfraReDx, Inc., an innovative medical device company focused on developing novel diagnostic imaging technologies to accurately identify and characterize diseased coronary tissue and guide therapeutic interventions, today announced that its next-generation LipiScan IVUS Coronary Imaging System will be featured at EuroPCR 2010, an international educational conference focused on introducing the latest techniques, updates and breakthrough science to the interventional cardiology community. EuroPCR is being held in Paris, France, from May 25 28, at the Palais des Congres Paris convention center.

As a highlight of EuroPCR’s “Glimpse into the Future” session being held on Thursday, May 27, 1:30 pm 4:30 pm (CEST), a “live case” demonstration of the LipiScan IVUS Coronary Imaging System will be broadcast from the Thoraxcenter of the Erasmus University Medical Center in Rotterdam, under the direction of Professor Willem J. van der Giessen and Dr. Nicolas Van Mieghem. The LipiScan IVUS system was developed by InfraReDx in collaboration with clinicians and researchers at the Biomedical Engineering department of the Thoraxcenter. It is a one-catheter, single-pullback system and the only coronary imaging device known to combine both intravascular ultrasound (IVUS) technology and near-infrared (NIR) spectroscopy to identify and characterize lipid-core containing plaque (LCP).

Lipid-core containing plaque is believed to be “vulnerable plaque” that can rupture and form dangerous blood clots, leading to coronary thrombosis. LCP is widely considered to be responsible for a significant number of stenting procedure complications, and is believed to be the primary cause of acute coronary events, the leading cause of death in the developed world.

The LipiScan IVUS system is expected to become commercially available in the U.S. during the second half of 2010 and in Europe during 2011. InfraReDx currently markets its first-generation LipiScan NIR system, which is the only FDA-cleared product to incorporate near-infrared imaging to identify and assess the chemical composition of coronary plaque, particularly LCP. The addition of complementary IVUS imaging technology to the LipiScan platform enhances its capabilities by also allowing for structural assessment of coronary plaque. LipiScan IVUS was designed to provide physicians with a “one-stop” determination of critical coronary health factors that guide patient care, including: chemical composition, degree of stenosis, stent expansion, plaque burden, estimation of cap thickness and extent of positive remodeling.

“The interventional cardiology community attending EuroPCR will be looking with great interest at the LipiScan IVUS system, as it represents an important technological advance in patient care,” said Evelyn Regar, M.D., Ph.D., interventional cardiologist at the Thoraxcenter and co-chairperson for the EuroPCR session. “The ability to at once assess the presence, makeup and structure of lipid-core vulnerable plaques would be of great utility during stenting procedures. It is our hope and expectation that the improved imaging and diagnostic capabilities offered by the LipiScan IVUS system will result in reduced stenting complications and better informed treatment decisions for patients with coronary artery disease.”

“I am eager to view the live case demonstration of LipiScan IVUS,” stated James Goldstein, M.D., Director of Cardiac Research and Education for Beaumont Hospital in Michigan. “The first-generation LipiScan NIR system is already in use at our hospital, and its chemogram information has already begun providing very promising results. The addition of structural IVUS data via a single catheter and in a single pull-back procedure would further elevate the system’s practical clinical utility for characterizing coronary lesions to reduce stenting complications and better guide cardiac care.” Dr. Goldstein, who has been involved in vulnerable plaque related research for over 10 years, currently serves as a consultant to InfraReDx as well as other medical device and imaging technology companies.

Each year, over 2 million individuals worldwide undergo coronary stenting. While clinical results of stenting procedures have steadily improved, approximately 30% of individuals undergoing percutaneous coronary intervention (PCI) experience a significant adverse event such as peri-stenting myocardial infarction, post-procedure complications from the stented site, or new coronary events at non-stented sites. In most cases, stenting is guided primarily by X-ray angiography, which does not reveal the health of the vessel wall. Increasingly, physicians are recognizing the limitations of relying on angiography alone and are turning to advanced imaging solutions system to optimize their stenting strategy.

About InfraReDx, Inc.

InfraReDx, Inc., headquartered in Burlington, Massachusetts, is a privately-funded medical device company founded in 1998 and focused on intravascular characterization of disease in the coronary arteries. InfraReDx is the maker of the LipiScan system, a novel near-infrared (NIR) spectroscopy catheter that can detect the lipid core coronary plaques suspected to cause most heart attacks and known to complicate stenting procedures. For more information, visit www.infraredx.com.

About EuroPCR

EuroPCR, the official congress of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), is a leading global cardiovascular course based in Europe. Its innovative and patient-centred approach assures the educational experience of more than 12,000 attendees annually. The EurpPCR program is based on interactivity, exchange between peers and a true multi-disciplinary team approach. PCR is dedicated to education in cardiovascular interventions. Its branches cover international conferences and seminars, an online reference source and scientific publications. PCR aims to energise the scientific community by sharing knowledge and increasing exchanges between peers. For more information, visit www.europcr.com.

SOURCE InfraReDx, Inc.